Search research articles
Contact Us
Filters
Showing results (1-10 of 65) with videos related to
Page
of 7
Sort By:
Arthritis Research & Therapy
|
December 19, 2003
Are synovial biopsies of diagnostic value?
Barry Bresnihan
The Journal of Rheumatology. Supplement
|
September 19, 2002
Preventing joint damage as the best measure of biologic drug therapy
Barry Bresnihan
The Journal of Rheumatology. Supplement
|
November 19, 2002
Rheumatoid arthritis: principles of early treatment
Barry Bresnihan
Current Opinion in Rheumatology
|
June 10, 2006
Synovial biomarkers in the spondylarthropathies
Barry Bresnihan
Current Opinion in Rheumatology
|
June 6, 2008
Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies
Joseph Keane, Barry Bresnihan
Rheumatic Diseases Clinics of North America
|
March 15, 2003
Infection complications associated with the use of biologic agents
Barry Bresnihan, Gaye Cunnane
Rheumatology (Oxford, England)
|
September 24, 2009
Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis
Patricia Minnock, John Kirwan, Barry Bresnihan
Best Practice & Research. Clinical Rheumatology
|
June 6, 2003
Infections and biological therapy in rheumatoid arthritis
Gaye Cunnane, Michele Doran, Barry Bresnihan
Arthritis and Rheumatism
|
April 11, 2003
Quality of life, social support, and knowledge of disease in women with rheumatoid arthritis
Patricia Minnock, Oliver Fitzgerald, Barry Bresnihan
Clinical Rheumatology
|
February 22, 2008
Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry
Eithne Murphy, Barry Bresnihan, Oliver FitzGerald
Page
of 7
Search research articles
Search
Showing results (1-10 of 65) with videos related to
Sort By:
Page
of 7
Arthritis Research & Therapy
|
December 19, 2003
Are synovial biopsies of diagnostic value?
Barry Bresnihan
The Journal of Rheumatology. Supplement
|
September 19, 2002
Preventing joint damage as the best measure of biologic drug therapy
Barry Bresnihan
The Journal of Rheumatology. Supplement
|
November 19, 2002
Rheumatoid arthritis: principles of early treatment
Barry Bresnihan
Current Opinion in Rheumatology
|
June 10, 2006
Synovial biomarkers in the spondylarthropathies
Barry Bresnihan
Current Opinion in Rheumatology
|
June 6, 2008
Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies
Joseph Keane, Barry Bresnihan
Rheumatic Diseases Clinics of North America
|
March 15, 2003
Infection complications associated with the use of biologic agents
Barry Bresnihan, Gaye Cunnane
Rheumatology (Oxford, England)
|
September 24, 2009
Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis
Patricia Minnock, John Kirwan, Barry Bresnihan
Best Practice & Research. Clinical Rheumatology
|
June 6, 2003
Infections and biological therapy in rheumatoid arthritis
Gaye Cunnane, Michele Doran, Barry Bresnihan
Arthritis and Rheumatism
|
April 11, 2003
Quality of life, social support, and knowledge of disease in women with rheumatoid arthritis
Patricia Minnock, Oliver Fitzgerald, Barry Bresnihan
Clinical Rheumatology
|
February 22, 2008
Measurement of periarticular bone mineral density in the hands of patients with early inflammatory arthritis using dual energy x-ray absorptiometry
Eithne Murphy, Barry Bresnihan, Oliver FitzGerald
Page
of 7